Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center.

Objectives: The aim of the study was to evaluate the use of F-fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) in the follow-up and clinical management of ovarian cancer patients after therapy.

Materials And Methods: A total of 152 ovarian cancer patients who had undergone therapy were evaluated. Clinical information, CA-125 levels, and traditional imaging findings were analyzed.

Comparison of the effect of positive and negative oral contrast agents on (18)F-FDG PET/CT scan.

Unlabelled: Our aim was to compare the effect of orally taken 1% diatrizoate meglumine, 5% mannitol and water before positron emission tomography/computerized tomography (PET/CT) scan on gastrointestinal tract delineation and fluorine-18-fluorodeoxyglucose ((18)F-FDG) uptake. Our methods were as follows: Sixty-one patients referred for PET/CT scan without gastrointestinal diseases were divided into three groups. One thousand mL of 1% diatrizoate meglumine was orally taken 50 min before PET/CT scan in Group 1 (n=25), 1000 mL 2.

Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan.

Objectives: Although dual-time-point scans have been widely used to improve the diagnostic efficacy of FDG PET in differentiating between malignant and benign lesions, no optimized delayed scan time-point has yet been recommended in clinical practice. Our study aimed to explore the most appropriate time for a delayed scan by comparing early and late delayed scans.

Methods: Eighty patients with suspected malignancy were given a three-phase (64 min, 110 min, 233 min after FDG injection) PET/CT scan.